Anti-fibrotic Drug Discovery
Seiten
2020
Royal Society of Chemistry (Verlag)
978-1-78801-510-3 (ISBN)
Royal Society of Chemistry (Verlag)
978-1-78801-510-3 (ISBN)
Anti-fibrotic Drug Discovery is ideal for postgraduate students and researchers with an interest in anti-fibrotic drug discovery as well as clinicians specialising in liver, kidney, heart and lung disease, in which fibrosis plays a key role in pathology.
Fibrosis is a condition with globally high unmet medical need, and as such is a highly active area of academic and pharmaceutical research covering multiple treatment targets, organs, tissues and therapeutic approaches. Anti-fibrotic Drug Discovery is a single source reference for the latest drug-discovery approaches to tackle fibrosis in various tissues, comprehensively covering recent success and future perspectives on emerging therapeutic intervention points. The book highlights significant pre-clinical and clinical drugs currently being developed globally for this disorder. This book is ideal for postgraduate students and researchers with an interest in anti-fibrotic drug discovery as well as clinicians specialising in liver, kidney, heart and lung disease, in which fibrosis plays a key role in pathology.
Fibrosis is a condition with globally high unmet medical need, and as such is a highly active area of academic and pharmaceutical research covering multiple treatment targets, organs, tissues and therapeutic approaches. Anti-fibrotic Drug Discovery is a single source reference for the latest drug-discovery approaches to tackle fibrosis in various tissues, comprehensively covering recent success and future perspectives on emerging therapeutic intervention points. The book highlights significant pre-clinical and clinical drugs currently being developed globally for this disorder. This book is ideal for postgraduate students and researchers with an interest in anti-fibrotic drug discovery as well as clinicians specialising in liver, kidney, heart and lung disease, in which fibrosis plays a key role in pathology.
TGFβ Signaling;
Targeting the αv Integrins in Fibroproliferative Disease;
Discovery, Structural Refinement and Therapeutic Potential of Farnesoid X Receptor Activators;
Autotaxin Inhibitors in Fibrosis;
Inhibition of LOXL2 and Other Lysyl Oxidase (Like) Enzymes: Intervention at the Core of Fibrotic Pathology;
Targeting the Ubiquitin Proteasome System in Pulmonary Fibrosis;
Galectin-3 Involvement in Fibrotic Diseases;
Emerging Role of CXCR4 in Fibrosis;
BH3 Mimetic Drugs for Anti-fibrotic Therapy;
Intratumoral Fibrosis: Emerging Concepts and Therapeutic Opportunities;
Targeting Fibroblasts in Fibrosis and Cancer
Erscheinungsdatum | 08.01.2019 |
---|---|
Reihe/Serie | Drug Discovery ; Volume 73 |
Verlagsort | Cambridge |
Sprache | englisch |
Maße | 156 x 234 mm |
Gewicht | 708 g |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
Medizin / Pharmazie ► Pharmazie | |
Naturwissenschaften ► Chemie ► Organische Chemie | |
ISBN-10 | 1-78801-510-X / 178801510X |
ISBN-13 | 978-1-78801-510-3 / 9781788015103 |
Zustand | Neuware |
Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Arzneimittelverzeichnis für Deutschland (einschließlich …
Buch | Hardcover (2024)
Rote Liste Service GmbH (Verlag)
CHF 149,95
Englisch für Apotheker und PTAs
Buch | Spiralbindung (2024)
Kohlhammer (Verlag)
CHF 44,75